All In Biotech

Drug Trial Radar · NCT07659184

IRONCARE: Iron Treatment in Older Patients With Hip Fractures

IRONCARE: Iron Treatment in Older Patients With Hip Fractures - A Double-blinded Placebo-controlled Randomized Trial

Last checked: Nov 20, 2026Latest source record: Jun 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 528 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

528

Planned (sponsor's estimate)

Start

Oct 1, 2026

Primary completion

Sep 30, 2028

Study completion Sep 30, 2028

Sponsor

Lead sponsor
University of AarhusAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Region MidtJylland Denmark; Viborg Regional Hospital; Gødstrup Hospital; Aarhus University Hospital; Randers Regional Hospital; Regionshospitalet Horsens
First posted
Jun 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to investigate the effects of intravenous (IV) iron therapy compared to alternate-day oral iron treatment and no supplementation in older patients with hip fractures. This study will examine the impact of iron treatment on fatigue, functional decline, fear of falling, cognitive impairment, and quality of life, as well as its effects on iron stores and hemoglobin levels, with the overall goal of improving postoperative rehabilitation. The trial will be conducted on five different hospitals in the Central Region of Denmark (Region Midtjylland).

Conditions

  • Hip Fracture
  • Anemia
  • Iron
  • Placebo - Control

Interventions

  • Ferric DerisomaltoseDrug

    Intravenous Ferric Derisomaltose shortly after surgery and placebo tablets on alternate days for 90 days

  • Oral Iron (Ferrous sulphate)Drug

    Oral iron sulfate on alternate days for 90 days and IV placebo once shortly after surgery

  • Placebo IVDrug

    100 ml Sodium Chloride (NaCl)

  • Placebo TabletsDrug

    Placebo tablets on alternate days for 90 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. FatigueTime frame: Baseline and days 30 and 90 after discharge
  2. Hemoglobin incrementTime frame: Baseline and days 30 and 90 after discharge
  3. Safety profileTime frame: Days 15, 30, 45 and 90 after discharge

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Aarhus Univeristy Hospital

    Aarhus N, Denmark

  • Regional Hospital Gødstrup

    Herning, Denmark

  • Regional Hospital Horsens

    Horsens, Denmark

  • Regional Hospital Randers

    Randers, Denmark

  • Regional Hospital Viborg

    Viborg, Denmark

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.